Analystreport

BioMarin Pharmaceutical (NASDAQ: BMRN) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $112.00 price target on the stock.

BioMarin Pharmaceutical Inc.  (BMRN) 
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.biomarin.com